Skip to content
Review Open access

Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review

Aug 2026 · International Journal of Molecular Sciences · Vol 27, pp. 7596 · 0 citations · 43 references
Medicine

TL;DR

Current randomized evidence remains limited but suggests that intravenous MSC therapy is generally well tolerated in older adults with aging frailty and may produce clinically relevant signals of improvement in mobility-related functional outcomes, quality of life, and selected inflammatory, immune, and vascular biomarkers.

Abstract

Aging frailty is a multifactorial geriatric syndrome characterized by reduced physiological reserve across multiple interrelated systems, leading to increased vulnerability to adverse health outcomes. Mesenchymal stem cells (MSCs) have emerged as a potential therapeutic intervention due to their immunomodulatory and regenerative properties. This systematic review aimed to evaluate the available clinical evidence regarding the safety and efficacy of MSC administration in individuals with aging frailty. A systematic literature search was conducted in PubMed, Scopus, and the Cochrane Library from database inception to 15 April 2026. Only randomized controlled trials (RCTs) were eligible. Data were extracted according to study design, participants’ characteristics, MSC source and dosing, safety outcomes, functional performance measures, quality of life (QoL) indices, and inflammatory, immune, and vascular biomarkers. Three RCTs met the inclusion criteria, comprising a total of approximately 208 participants. MSC administration was well-tolerated, with no treatment-related serious adverse events reported. Signals of improvement were reported in mobility-related and physical performance outcomes, although the magnitude and consistency of the response varied across studies. A dose-dependent increase in 6 min walk distance was observed at nine months in one trial, while improvements in SPPB, TUG, and grip strength were reported in the other studies. Additionally, MSC therapy was associated with QoL improvement and reduction in circulating pro-inflammatory cytokine concentrations. MSC administration was also associated with changes in immune-cell activation and a dose-dependent reduction in circulating sTIE2. Because of substantial clinical and methodological heterogeneity among the included trials, a quantitative meta-analysis was not performed. Current randomized evidence remains limited but suggests that intravenous MSC therapy is generally well tolerated in older adults with aging frailty and may produce clinically relevant signals of improvement in mobility-related functional outcomes, quality of life, and selected inflammatory, immune, and vascular biomarkers. However, the small number of trials, heterogeneity in MSC source, dose, endpoints, and follow-up duration, and the exploratory nature of much of the evidence preclude definitive conclusions regarding efficacy. Larger, adequately powered trials with standardized frailty endpoints are required, while future trials specifically targeting sarcopenia should apply consensus diagnostic criteria and direct measures of muscle quantity, strength, and physical performance.

Read PDF

Similar papers

Open access Sep 2026

Efficacy and safety of stem cell therapy as compared to standard care in patients with spinal cord injury: A meta-analysis

Stem cell intervention shows promise for treating spinal cord injury (SCI) through regenerative mechanisms. This study aimed to thoroughly assess the efficacy and safety of stem cell therapy in SCI patients compared to standard care. Databases such as Cochrane Central, EMBASE, Web of Science, and PubMed we...

P. Tangri, M. Nath, Bhoomika Arora et al. · 0 citations
Review Open access Oct 2026

Stem Cell Therapy in Alzheimer’s Disease: a Scoping Review of Safety, Efficacy and Clinical Insights

Alzheimers disease (AD) remains a progressive neurodegenerative disorder with limited disease-modifying treatment approaches. This scoping review aimed to systematically examine and critically evaluate the existing clinical evidence on stem cell therapy for AD, focusing on therapeutic efficacy, safety, cognitive and fu...

Prabir Maity, Ayushi Nayak, Gracy Sharma et al. · 0 citations
Review Sep 2026

Mesenchymal Stem Cell Therapy for Ischemic Stroke: Bridging Clinical Evidence and Translational Challenges.

This Concise Review synthesizes the current clinical evidence supporting MSC therapy for ischemic stroke, critically examines the biological and translational determinants of therapeutic efficacy, and discusses emerging strategies, including engineered MSCs, extracellular vesicle (EV)-based therapies, and integration w...

Samson Selvaraj · 0 citations
Review Open access Oct 2026

Cell-based therapies in spinal cord injury: systematic review and meta-analysis of randomized controlled trials

Background: Spinal cord injury (SCI) is a severe neurological condition leading to permanent motor, sensory, and autonomic deficits, with major functional impairment and limited restorative treatment options. Cell-based therapies have emerged as a promising regenerative strategy due to their neuroprotective, immunomodu...

Maria R. Mascarenhas, A. Rodrigues, L. Ferreira et al. · 0 citations
Review Open access Nov 2026

Clinical and Structural Outcomes of Platelet-Rich Plasma and Mesenchymal Stromal Cell Therapies for Knee Osteoarthritis: A Systematic Review

Background: Knee osteoarthritis is a highly prevalent degenerative condition, characterized by chronic pain, joint stiffness, and functional limitation, with a significant impact on quality of life. Conventional therapies have limited efficacy, especially in the moderate and advanced stages of the disease. In this cont...

J. P. Mundim, Rodrigo Franco de Oliveira, T. M. de Faria Sudré et al. · 0 citations
Review Open access Oct 2026

Geriatric Regenerative Medicine: Mechanisms, Strategies, and Clinical Translation

Population aging has intensified interest in interventions that preserve function and delay disability. However, regenerative strategies for older adults are often discussed as isolated technologies, with limited attention to how aging biology alters therapeutic responses or how clinical benefit should be measured. W...

Qiang Li, Chao-Yang Wang, Jun-Ci Chong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.